News

Latest News

We’re proud of our team for the recent successful delivery of a client project using Hypha’s One-Stop Metabolite Shop approach. Metabolites of two drug substances were provided, using microbial biotransformation for one drug compound and late-stage chemical synthesis for the other.

We always really appreciate receiving feedback from a client. This time we celebrate project success for Alkermes for whom we used our PolarExplorer platform to deliver novel hydroxylated derivatives of some of their lead compounds. PolarExplorer uses Hypha’s PolyCYPs enzymes to create multiple hydroxylated derivatives of drugs in parallel.

Project Manager and Head of Chemistry Richard Phipps, together with Hypha scientists Renia Gemmell, Chloe Herring and Chris Drake have received great feedback for the successful completion of a challenging metabolite project for a US pharma client. The project involved multiple disciplines of microbial biotransformation, purification and structure elucidation.

Hypha were honoured to be asked to contribute a chapter on “Metabolite Generation and Metabolite Characterization by NMR” in the book just published on “Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters”, edited by Shuguang Ma and Swapan Chowdhury.

Hypha are excited to announce they have relocated from Slough to Milton Park in Oxfordshire, one of the largest science clusters in the UK.

Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites.

Ready to begin? Our scientists are available to talk through your requirements

Contact Us

Subscribe to our newsletter and blog!

Newsletter Signup
Which do you wish to signup for?

Don't forget to subscribe to our newsletter and blog!

Newsletter Signup
Which do you wish to signup for?